Fennec Pharmaceuticals Inc. (FRA:RV41)
Germany flag Germany · Delayed Price · Currency is EUR
6.20
+0.05 (0.81%)
At close: Jan 30, 2026

Fennec Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
21.9526.6313.2723.7721.130.34
Cash & Short-Term Investments
21.9526.6313.2723.7721.130.34
Cash Growth
-45.57%100.72%-44.19%12.67%-30.46%122.30%
Receivables
19.3412.888.811.55--
Inventory
2.481.062.160.58--
Prepaid Expenses
1.43.082.580.771.030.8
Other Current Assets
0.90.470.040.060.250.28
Total Current Assets
46.0644.1226.8626.7322.3931.42
Long-Term Deferred Charges
0.740.820.010.210.03-
Total Assets
49.2644.9526.8626.9422.4131.42
Accounts Payable
5.873.243.782.390.781.57
Accrued Expenses
3.73.433.752.220.880.78
Current Portion of Leases
-00.02---
Current Unearned Revenue
0.250.25----
Total Current Liabilities
9.826.927.554.611.652.35
Long-Term Debt
19.3819.3430.9324.94.99-
Long-Term Unearned Revenue
24.5624.560---
Total Liabilities
53.7550.8238.4929.516.642.35
Common Stock
147.65145.61144.31142.59140.8140.73
Additional Paid-In Capital
71.2566.9662.0756.853.2149.23
Retained Earnings
-224.64-219.68-219.25-203.2-179.49-162.14
Comprehensive Income & Other
1.241.241.241.241.241.24
Shareholders' Equity
-4.49-5.87-11.62-2.5715.7729.07
Total Liabilities & Equity
49.2644.9526.8626.9422.4131.42
Total Debt
19.3819.3430.9524.94.99-
Net Cash (Debt)
2.577.29-17.68-1.1316.1130.34
Net Cash Growth
-68.72%----46.90%122.30%
Net Cash Per Share
0.090.27-0.67-0.040.621.28
Filing Date Shares Outstanding
28.1227.5927.126.4126.0126
Total Common Shares Outstanding
28.0627.5327.0326.3626.0126
Working Capital
36.2537.2119.3122.1220.7329.07
Book Value Per Share
-0.16-0.21-0.43-0.100.611.12
Tangible Book Value
-4.49-5.87-11.62-2.5715.7729.07
Tangible Book Value Per Share
-0.16-0.21-0.43-0.100.611.12
Source: S&P Global Market Intelligence. Standard template. Financial Sources.